Yes — this is a genuinely significant development.
Researchers reported that an experimental pill called Daraxonrasib has nearly doubled survival time for some people with advanced pancreatic cancer in a large clinical trial.
What happened?
In the phase 3 trial:
- Patients taking daraxonrasib lived a median of 13.2 months
- Compared with 6.7 months for patients receiving standard chemotherapy
That’s roughly double the average survival time.
Why is it important?
Pancreatic cancer is one of the hardest cancers to treat, and survival rates have improved only slowly over decades. Doctors are calling this one of the biggest breakthroughs in years because:
- the drug targets the KRAS/RAS mutation, found in over 90% of pancreatic cancers
- KRAS was long considered “undruggable”
- the pill also appeared to have fewer severe side effects than some chemotherapy options in the trial
Important to keep in mind
- It is not a cure.
- The results are mainly in people with advanced/metastatic pancreatic cancer, especially after prior treatment.
- The drug is still investigational, meaning approval and wider access are still being worked through.
But many cancer specialists are calling it a major step forward and a real source of hope.
If you saw a specific article about it and want me to break down any part of it in simpler language, paste it here.
